Moleculin Biotech is trading 5.56% up now at $0.55 after falling sharply to $0.52 on September 21, 2026; no new company-specific announcement explaining the September 22 pre-market rise was identified.
- The latest material disclosure remains Nasdaq’s delisting notice for sustained sub-$1 closing bids.
- Moleculin plans to request a hearing, which would temporarily stay suspension or delisting.
- The modestly positive broader market does not provide a strong direct catalyst.